Breast Cancer Therapy
Women switched to anastrozole treatment have improved event-free survival
Published in Women's Health Weekly, December 15th, 2005
According to researchers from Austria, "Tamoxifen has been the standard adjuvant treatment for postmenopausal women with hormone-responsive early breast cancer for more than 20 years. However, the third-generation aromatase inhibitor anastrozole has proven efficacy and tolerability benefits compared with tamoxifen when used as initial adjuvant therapy."
R. Jakesz and colleagues "investigated whether women who have received a period of adjuvant tamoxifen would benefit from being switched to anastrozole. They presented a combined analysis of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Breast Cancer
Breast cancer cells are prone to apoptosis and growth arrest after protein silencing - Chlamydia
Male circumcision could reduce Chlamydia trachomatis infection in female partners - Kidney Disease
Study suggests two-thirds of patients with chronic kidney disease go undiagnosed - Sexual & Reproductive Health
Pregnancy achieved in fertile partners of patients after prostate brachytherapy - Women's Health
Researchers advocate extending definition of women's health to include chronic diseases - Apoptosis
Micromolar taxol induced cell necrosis in HeLa cells - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
